Outlook Therapeutics (OTLK) Common Equity: 2015-2020
Historic Common Equity for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to $11.0 million.
- Outlook Therapeutics' Common Equity rose 267.27% to $11.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $11.0 million, marking a year-over-year increase of 267.27%. This contributed to the annual value of -$16.1 million for FY2019, which is 36.86% up from last year.
- Latest data reveals that Outlook Therapeutics reported Common Equity of $11.0 million as of Q2 2020, which was up 153.43% from -$20.5 million recorded in Q1 2020.
- Outlook Therapeutics' Common Equity's 5-year high stood at $11.0 million during Q2 2020, with a 5-year trough of -$37.9 million in Q1 2016.
- Moreover, its 3-year median value for Common Equity was -$23.0 million (2018), whereas its average is -$19.0 million.
- Its Common Equity has fluctuated over the past 5 years, first plummeted by 1,951.51% in 2017, then surged by 267.27% in 2020.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Common Equity stood at -$21.8 million in 2016, then fell by 14.92% to -$25.1 million in 2017, then fell by 5.05% to -$26.4 million in 2018, then dropped by 17.37% to -$30.9 million in 2019, then skyrocketed by 267.27% to $11.0 million in 2020.
- Its Common Equity was $11.0 million in Q2 2020, compared to -$20.5 million in Q1 2020 and -$30.9 million in Q4 2019.